Physio4FMD: protocol for a multicentre randomised controlled trial of specialist physiotherapy for functional motor disorder
Year: 2019
Type: article
Study design: Study Protocol
Abstract: BACKGROUND: Patients with functional motor disorder (FMD) experience persistent and disabling neurological symptoms such as weakness, tremor, dystonia and disordered gait. Physiotherapy is usually considered an important part of treatment; however, sufficiently-powered controlled studies are lacking. Here we present the protocol of a randomised controlled trial (RCT) that aims to evaluate the clinical and cost effectiveness of a specialist physiotherapy programme for FMD. METHODS/DESIGN: The trial is a pragmatic, multicentre, single blind parallel arm randomised controlled trial (RCT). 264 Adults with a clinically definite diagnosis of FMD will be recruited from neurology clinics and randomised to receive either the trial intervention (a specialist physiotherapy protocol) or treatment as usual control (referral to a community physiotherapy service suitable for people with neurological symptoms). Participants will be followed up at 6 and 12 months. The primary outcome is the Physical Function domain of the Short Form 36 questionnaire at 12 months. Secondary domains of measurement will include participant perception of change, mobility, health-related quality of life, health service utilisation, anxiety and depression. Health economic analysis will evaluate the cost impact of trial and control interventions from a health and social care perspective as well as societal perspective. DISCUSSION: This trial will be the first adequately-powered RCT of physical-based rehabilitation for FMD. TRIAL REGISTRATION: International Standard Randomised Controlled Trials Number ISRCTN56136713 . Registered 27 March 2018.
Source: BMC Neurology
Authors: on behalf of the Physio4FMD Collaborative Group, Glenn Nielsen, Jon Stone, Marta Buszewicz, Alan Carson, Laura H. Goldstein, Kate Holt, Rachael Hunter, Jonathan Marsden, Louise Marston, Hayley Noble, Markus Reuber, Mark J. Edwards
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,380
Funders: Teva Pharmaceutical Industries, South London and Maudsley NHS Foundation Trust, NHS Health Scotland, LivaNova, National Institute for Health and Care Research, Department of Health and Social Care, Guarantors of Brain, King's College London, University of Oxford, Eisai, Merz Pharmaceuticals, NIHR Maudsley Biomedical Research Centre, Medical Research Council, Health Technology Assessment Programme
OpenAlex ID: W2980962023
